New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
October 5, 2018 - Akcea Therapeutics and Ionis Pharmaceuticals announced the FDA approval of Tegsedi (inotersen), for treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
Download PDF
Return to publications
